intelligentis successfully advised PharmAI Discovery, a leading European drug discovery specialist based on artificial intelligence, on its current fundraise round. Despite difficult fundraise conditions, a sum of €5.0 million could be secured from a private industry investor as a result of the investor approach. PharmAI Discovery will use the capital raised to drive forward the development of its platform and the globalization of its business model.

About PharmAI Discovery

PharmAI Discovery GmbH, based in Germany, has developed a cutting-edge platform based on artificial intelligence to identify new and promising active pharmaceutical compounds. The platform utilizes three-dimensional analyses to precisely characterize the binding mechanisms of molecules. In addition, PharmAI Discovery’s proprietary AI algorithm is designed specifically for the development of disruptive drugs, including both small molecule radiolabeled and conventional therapies. After identification, promising compounds are tested and optimized in laboratories. The process developed by PharmAI Discovery outperforms similar in-silico drug discovery methods, as independently verified.
Backed by more than 20 years of research, PharmAI Discovery combines scientific expertise with innovative AI technology to deliver superior drug discovery solutions. The primary target markets are oncology and pan-virology. Since its spin-off from the Technical University of Dresden, PharmAI Discovery has evolved into a leading research company in the healthcare sector and expects to generate revenues of over €600 million by 2030.

About intelligentis

intelligentis, based in Dresden (Germany), is a specialized M&A boutique that supports medium-sized companies throughout Europe in sell-side processes, capital raise projects and strategic acquisitions. With in-depth market knowledge in all relevant sectors and an analytically-based approach, intelligentis creates long-term and sustainable value for entrepreneurs, investors and family offices.